@misc{Prochwicz_Anna_Clinical_2020,
 author={Prochwicz, Anna},
 address={Kraków},
 howpublished={online},
 year={2020},
 school={Rada Dyscypliny Nauki medyczne},
 language={pol},
 abstract={Essential thrombocythemia belongs to chronic Ph-negative myeloproliferative neoplasms. The disease may undergo transformation into myelofibrosis or acute leukemia and contribute to the occurrence of thromboembolic complications and thus lead to a significant shortening of life. Non-hematological cancers are also more often diagnosed in this group of patients. The study attempts to determine clinical and laboratory factors that would allow the selection of patients at increased risk of aggressive course of disease or appeared complications. The study group consisted of 243 patients diagnosed with essential thrombocythemia in the years 1993-2018 at the SU Hematology Clinic in Krakow, eithter treated with hydroxyurea or anagrelide or not receiving cytoreductive therapy. Significant proved: for disease progression - LDH and CRP level and for the occurrence of a second non-hematological cancer and arterial thrombosis - β2-microglobulin. What is more, the impact of splenomegaly at the time of diagnosis as an indicator of disease progression and the risk of venous thrombosis was confirmed. Considering the following observation results: higher risk of not achieving CR in patients with a platelet count above 1 OOO 000/μl, the increased risk of venous thrombosis in patients who required a change in cytoreductive treatment (HU to anagrelide ), decreased risk of progression with the},
 abstract={duration of treatment, it seems rational to start cytoreductive therapy with lower platelet counts rather than the currently recommended limit of > 1 500 000/μl, especially for patients with the current JAK2 mutation.},
 title={Clinical and laboratory factors influencing on the prognosis and occurrence of thromboembolic complications and secondary cancers in patients suffering from essential thrombocythemia},
 type={Praca doktorska},
 keywords={essential thrombocythemia, hydroxyurea, anagrelide, secondary cancers, thrombosis},
}